ABVC BioPharma, Inc.
ABVC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -161% | – | – | -1,530.5% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -156.6% | – | – | 11,663.5% |
| EPS Diluted | -0.054 | -0.13 | -0.06 | 0.017 |
| % Growth | 58.8% | -116.7% | -448.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |